

## CORRELATION BETWEEN SERUM LEVELS OF HMGB1 AND A $\beta$ WITH DISEASE SEVERITY IN PATIENTS WITH ACUTE ISCHEMIC STROKE

JIEPING ZHONG, LIANHUA QIN, YILING ZHANG, YANAN ZHANG\*

Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China

### ABSTRACT

**Objective:** To explore the correlation between serum levels of HMGB1 and A $\beta$  and disease severity in patients with acute ischemic stroke (AIS).

**Methods:** The data of 100 patients with AIS admitted to our hospital from February 2020 to February 2021 were selected for retrospective analysis. According to the National Institutes of Health Stroke Scale (NIHSS) score within 24 hours of admission, the patients were divided into the light group (LG), moderate group (MG) and severe group (SG), and 30 cases with health examination were the control group (CG). After taking the serum of patients, the levels of HMGB1 and A $\beta$  were measured to compare their differences among different groups and analyze the correlation between the levels of HMGB1 and A $\beta$  and the degree of neurological deficits.

**Results:** The NIHSS score in the LG was overtly lower than the MG and SG ( $P < 0.001$ ), and the NIHSS score in the MG was visibly lower than the SG ( $P < 0.001$ ). The levels of HMGB1 and A $\beta$  in the LG were clearly lower than the MG and SG ( $P < 0.001$ ), and higher than the CG ( $P < 0.001$ ). The preliminary analysis of scatter diagram showed a trend of linear correlation between serum levels of HMGB1 and A $\beta$  and NIHSS, with no obvious outlier. According to  $r$ -analysis, the correlation between serum HMGB1 level and NIHSS showed  $r = 0.930$ ,  $r^2 = 0.865$ ,  $t = 25.007$  and  $\text{Sig} < 0.001$ , and the correlation between A $\beta$  level and NIHSS showed  $r = 0.970$ ,  $r^2 = 0.941$ ,  $t = 39.488$  and  $\text{Sig} < 0.001$ .

**Conclusion:** The serum levels of HMGB1 and A $\beta$  in patients with AIS were positively correlated with the disease severity. In other words, the higher the serum levels of HMGB1 and A $\beta$ , the more severe the AIS.

**Keywords:** Acute ischemic stroke, HMGB1, A $\beta$ , correlation.

DOI: 10.19193/0393-6384\_2023\_1\_46

Received October 25, 2022; Accepted December 27, 2022

### Introduction

Acute ischemic stroke (AIS), with cerebrovascular atherosclerosis as basic pathological feature, is the most common type of stroke, accounting for about 70.0% of all acute cerebrovascular diseases, whose mortality is as high as 40.0% and disability rate is as high as 80.0%<sup>(1-3)</sup>, seriously endangering the lives and health of Chinese residents. At present, with the help of C-reactive protein and leukocyte count, the patients' condition was analyzed to give them early diagnosis and treatment as much as

possible, but such indicators cannot effectively assess disease progression and reduce patient mortality and disability rate<sup>(4)</sup>. In recent years, domestic and foreign literature have shown that some serum chemical indicators can evaluate the condition of ischemic stroke by reflecting the important pathological links of ischemic stroke<sup>(5-6)</sup>. For example, high mobility group box-1 protein (HMGB1), a nuclear protein in mononuclear macrophages, has a wide expression in eukaryotic cells and belongs to a delayed inflammatory mediator, which can regulate the production of oxygen free radicals and affect

oxidative stress response. Amyloid beta protein (A $\beta$ ) affects the oxidative stress response<sup>(7)</sup>, and is produced by  $\beta$ -secretase and  $\gamma$ -secretase via catalytic pyrolysis of amyloid precursor protein, which has strong neurotoxicity, exerting an important role in inducing neuronal apoptosis and the occurrence and development of atherosclerosis.

HMGB1 and A $\beta$  may have ideal value in evaluating the severity of patients with AIS, which is helpful to evaluate the development of patients and provide objective basis for treatment.

Therefore, this article will use the National Institutes of Health Stroke Scale (NIHSS) score as a medium to analyze the correlation between the levels of HMGB1 and A $\beta$  and NIHSS, then analyzing the actual value of NHMGB1 and A $\beta$ , with the results reported as follows.

## Materials and methods

### Study design

As a retrospective study, this study was conducted in our hospital from February 2020 to February 2021, aiming to explore the correlation between serum levels of HMGB1 and A $\beta$  and disease severity in patients with AIS.

This study was in accordance with the principles of Declaration of Helsinki (2013)<sup>(8)</sup>, and the patients and their family who were aware of the purpose, significance, content and confidentiality signed the informed content.

### Inclusion and exclusion criteria

From February 2020 to February 2021, the data of 100 patients with AIS in our hospital were selected for retrospective analysis, with the inclusion criteria as follows:

- Patients met the diagnostic criteria for AIS established by the fourth national academic meeting for cerebrovascular disease in 1995;
- The results of imaging examination in patients were in line with AIS;
- The time from first onset to admission was within 24 hours.

#### Exclusion criteria:

- Patients with intracranial hemorrhage;
- Patients with cranial trauma;
- Patients with cerebral infarction due to the vascular malformations;
- Patients with takayasu arteritis and cerebral infarction caused by autoimmune disease;
- Patients with coagulation disorders;

- Patients with hematological diseases;
- Patients with dysfunction in vital organs such as heart, liver and kidney.

### Methods and observational criteria

According to the NIHSS score<sup>[9]</sup> within 24 hours of admission, the patients were divided into the light group (LG), moderate group (MG) and severe group (SG), and 30 cases with health examination were the control group (CG). The NIHSS score was used to evaluate the degree of neurological deficits before and after treatment, including consciousness, gaze, visual field, facial paralysis, upper limb motion, lower limb motion, ataxia, sensation, language expression ability, dysarthria and neglect, with the total score as 42 points.

The mild neurologic impairment was less than 3 points, 4-15 points were moderate neurologic impairment, and severe neurologic impairment was more than 16 points. The fasting venous blood of the patients was taken to centrifuge at 3000 r/min for 5 min, and the supernatant was collected and stored at -20°C for test. After collecting the samples, the levels of HMGB1 and A $\beta$  were measured via enzyme-linked immunosorbent assay (Beijing Kewei Clinical Diagnostic Reagent Inc.; NMPA approval No.: S20060028) to compare the level differences of HMGB1 and A $\beta$  among different groups, and the correlation between the levels of HMGB1 and A $\beta$  and the degree of neurological deficit was evaluated by r-analysis.

### Statistical treatment

The software SPSS20.0 was used to analyze the experimental data, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was adopted to draw pictures of data. The enumeration data and measurement data in this study were tested by X<sup>2</sup> and t test. P<0.05 indicated a statistical significance in difference.

## Results


### Comparison of general information in patients

According to NIHSS score, there were 45 cases in the LG, 33 cases in the MG and 22 cases in the SG. Among them, there were 28 males and 17 females in the LG, with the average age of (55.33±5.24) years old and the body mass of (65.65±3.57) kg, the numbers in the MG were 20, 13, (54.30±5.29) years old and (65.74±3.50) kg, the numbers in the SG were 15, 7, (56.36±5.16) years old and (64.80±3.65) kg,

and the numbers in the CG were 19, 11, (55.37 $\pm$ 5.20) years old and (65.77 $\pm$ 3.45) kg, with no obvious difference in gender and age among the four groups ( $P>0.05$ ).

### Comparison of NIHSS scores in patients

The NIHSS score in the LG was overtly lower than the MG and SG ( $P<0.001$ ), and the NIHSS score in the MG was visibly lower than the SG ( $P<0.001$ ), as shown in Figure 1.




**Figure 1:** Comparison of NIHSS score in patients ( $\bar{x}\pm s$ , points).

Notes: The transverse axis showed the LG, MG and SG, and the vertical axis showed the NIHSS (points).

The NIHSS score in the LG was distinctly lower than the MG and SG (1.84 $\pm$ 0.76 vs 10.67 $\pm$ 2.88 vs 21.73 $\pm$ 3.49,  $P<0.001$ ).

### Comparison of serum levels of HMGB1 and A $\beta$ in patients

The levels of HMGB1 and A $\beta$  in the LG were clearly lower than the MG and SG ( $P<0.001$ ), and higher than the CG ( $P<0.001$ ), as shown in Figure 2.




**Figure 2:** Comparison of serum levels of HMGB1 and A $\beta$  in patients ( $\bar{x}\pm s$ ).

Notes: Figure 2A showed HMGB1 ( $\mu\text{g/ml}$ ) and Figure 2B showed A $\beta$  (pg/ml).


The HMGB1 level in the LG was clearly lower than the MG and SG (3.25 $\pm$ 0.55 vs 7.91 $\pm$ 2.10 vs 9.66 $\pm$ 1.41,  $P<0.001$ ), and higher than the CG (3.25 $\pm$ 0.55 vs 1.22 $\pm$ 0.54,  $P<0.001$ ), while the A $\beta$  level in the LG was overtly lower than the MG and SG (141.80 $\pm$ 7.30 vs 185.90 $\pm$ 19.13 vs 228.67 $\pm$ 14.06,  $P<0.001$ ), and higher than the CG (141.80 $\pm$ 7.30 vs 125.65 $\pm$ 9.65,  $P<0.001$ ).

### Scatter diagram of correlation between serum levels of HMGB1 and A $\beta$ and NIHSS

The preliminary analysis of scatter diagram showed a trend of linear correlation between serum levels of HMGB1 and A $\beta$  and NIHSS, with no obvious outlier. See Figure 3 and Figure 4.



**Figure 3:** Scatter diagram of correlation between serum HMGB1 level and NIHSS.



**Figure 4:** Scatter diagram of correlation between serum A $\beta$  level and NIHSS.

### R-analysis of correlation between serum levels of HMGB1 and A $\beta$ and NIHSS

According to r-analysis, the correlation between serum HMGB1 level and NIHSS showed

$r=0.930$ ,  $r^2=0.865$ ,  $t=25.007$  and  $\text{Sig}<0.001$ , and the correlation between  $A\beta$  level and NIHSS showed  $r=0.970$ ,  $r^2=0.941$ ,  $t=39.488$  and  $\text{Sig}<0.001$ .

## Discussion

AIS is caused by cerebral vascular atherosclerosis, and patients with intracranial vascular embolism and cerebral artery stenosis result in the reduction of cerebral blood flow and hypoxia and ischemia in blood supply of brain tissue, ultimately leading to acute brain dysfunction<sup>(10-11)</sup>. In the process of its development, oxidative stress reaction is an important pathological link, with the increase of oxygen free radicals as the main feature of oxidative stress activation, and it is not only involved in the formation of atherosclerotic plaques, but also participates in the brain tissue injury after hypoxia and ischemia<sup>(12-14)</sup>, but its specific mechanism is not clear. Zhang Xiaopeng<sup>(15)</sup> has found that the levels of total superoxide dismutase and glutathione peroxidase in the serum of patients with AIS are signally lower than the healthy control group, while the levels of 8-hydroxydeoxyguanosine and lipid peroxide are markedly higher than the healthy control group, which confirms that the excessive activation of oxidative stress reaction is closely related to the occurrence of ischemic stroke.

The contents of total superoxide dismutase and glutathione peroxidase in stroke patients with high HMGB1 content were prominently decreased, while the contents of 8-hydroxydeoxyguanosine and lipid peroxide were notably increased, confirming that the abnormal expression of HMGB1 could aggravate oxidative stress, and accelerate the generation of oxygen free radicals and the consumption of antioxidant enzymes.

This study found that the HMGB1 level in the LG was notably lower than the MG and the SG ( $P<0.001$ ), and higher than the CG ( $P<0.001$ ) by analyzing the HMGB1 levels of patients with AIS and healthy controls, which suggests that the HMGB1 level was closely related to the severity of brain injury, speculating the mechanism is that HMGB1, as a highly conserved nuclear protein in mononuclear macrophages, is secreted slightly by nerve cells and glial cells in normal conditions, and its release frequency increases under the influence of hypoxia and ischemia<sup>(16-17)</sup>. Then it exerts a proinflammatory effect by combining with the membrane receptor to trigger a cascade reaction of systemic inflammatory, which affects the stability

of the plate, thereby accelerating the formation of oxygen free radicals and aggravating brain tissue damage at the blood supply site<sup>(18)</sup>. Yang K et al.<sup>(19)</sup> have believed that HMGB1 is a inflammatory mediator in sepsis, rheumatoid arthritis and other inflammatory diseases, and excessive inflammatory response will aggravate craniocerebral injury. Liu Jing et al.<sup>(20)</sup> have reported that the HMGB1 level in patients with ischemic stroke was higher than the healthy subjects, and the HMGB1 level was positively correlated with NIHSS and mRS scores, suggesting that the HMGB1 level is related to the prognosis of patients with ischemic stroke.

The preliminary analysis of the scatter diagram in this paper showed that there was a trend of linear correlation between HMGB1 level and NIHSS, with no obvious outlier. According to r-analysis, the correlation between serum HMGB1 level and NIHSS showed  $r=0.930$ ,  $r^2=0.865$ ,  $t=25.007$  and  $\text{Sig}<0.001$ , indicating that the NIHSS score was affected by HMGB1 level in 86.5% of condition, which confirms the correlation between them.

In addition to HMGB1,  $A\beta$  also has an important relationship with oxidative stress<sup>(21-22)</sup>.  $A\beta$  is produced by  $\beta$ -secretase and  $\gamma$ -secretase via catalytic pyrolysis of amyloid precursor protein, with a strong neurotoxicity in extracellular matrix deposition, which could indirectly or directly product the lipid peroxidation, causing oxidative stress, thus leading to multiple diseases in combination with enkephalinase and insulin-degrading enzymes<sup>(23)</sup>. A large number of studies have confirmed that the marker is related to the development of diseases such as cerebral amyloid angiopathy and spinal cord injury. In cerebral amyloid angiopathy,  $A\beta$  can directly inhibit the secretion of fibroblast growth factor-2, so that a large number of fibers are deposited around the artery wall, resulting in amyloidosis in vascular function and morphology. Zhang Tian et al.<sup>(24)</sup> have believed that the neurotoxicity of  $A\beta$  is closely connected with the occurrence of stroke, which may be the main influencing factor of early neurological deterioration in patients with AIS. Qin Xue et al.<sup>(25)</sup> have shown that  $A\beta$  also has a high expression in patients with AIS, indicating that  $A\beta$  level exerts an important value in evaluating the condition of patients with AIS.

This study found that the  $A\beta$  level in the LG was signally lower than the MG and SG ( $P<0.001$ ), and higher than the CG ( $P<0.001$ ). The preliminary analysis of the scatter diagram showed that there was a tend of linear correlation between  $A\beta$  level

and NIHSS. According to r-analysis, the correlation between serum A $\beta$  level and NIHSS showed  $r=0.970$ ,  $r^2=0.941$ ,  $t=39.488$  and  $\text{Sig} < 0.001$ , which confirmed the value of A $\beta$  in evaluating the severity of patients.

In conclusion, the serum levels of HMGB1 and A $\beta$  in patients with AIS were positively correlated with the disease severity. In other words, the higher the serum levels of HMGB1 and A $\beta$ , the more severe the AIS.

## References

- 1) Zhang X F, Xu W D, Wu J, [Effect of left atrial enlargement on the prognosis of acute ischemic stroke]. [J]. *Zhonghua Yi Xue Za Zhi*, 2022, 102: 671-674.
- 2) Tang Guoyi, Cao Zhixin, Luo Yuting et al. Prognosis associated with asymptomatic intracranial hemorrhage after acute ischemic stroke: a systematic review and meta-analysis.[J]. *J Neurol*, 2022, 269: 3470-3481.
- 3) Xu Tian, Zhang Kaixin, Zhong Chongke et al. Plasma Human Cartilage Glycoprotein-39 Is Associated With the Prognosis of Acute Ischemic Stroke.[J]. *J Am Heart Assoc*, 2022, 11: e026263.
- 4) Li Jiejie, Pan Yuesong, Xu Jie et al. Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients. [J]. *Stroke*, 2021, 52: 2827-2836.
- 5) van Es Adriaan C G M, Hunfeld Maayke A W, van den Wijngaard Ido et al. Endovascular Treatment for Acute Ischemic Stroke in Children: Experience From the MR CLEAN Registry.[J]. *Stroke*, 2021, 52: 781-788.
- 6) Yang Pinni, Zhu Zhengbao, Zang Yuhan et al. Increased Serum Complement C3 Levels Are Associated With Adverse Clinical Outcomes After Ischemic Stroke.[J]. *Stroke*, 2021, 52: 868-877.
- 7) Liu Jia, Yuan Junliang, Zhao Jingwei et al. Serum metabolomic patterns in young patients with ischemic stroke: a case study.[J]. *Metabolomics*, 2021, 17: 24.
- 8) World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013 Nov 27; 310(20): 2191-4.
- 9) Chen Yong, Du Zhong-Heng, Chen Hai-Yan et al. [Effect of staged acupuncture on serum irisin level and neurological rehabilitation in patients with ischemic stroke]. [J]. *Zhongguo Zhen Jiu*, 2022, 42: 857-62.
- 10) Lai Minchao, Zhang Xiaojun, Zhou Danya et al. Integrating serum proteomics and metabolomics to compare the common and distinct features between acute aggressive ischemic stroke (APIS) and acute non-aggressive ischemic stroke (ANPIS).[J]. *J Proteomics*, 2022, 261: 104581.
- 11) Chukanova A S, Gulieva M S, Chukanova E I et al. [A panel of serum biomarkers, including damage, apoptosis and neurotrophic markers, for the assessment of prognosis of the course of ischemic stroke]. [J]. *Zh Nevrol Psikhiatr Im S S Korsakova*, 2022, 122: 48-53.
- 12) Wang Anxin, Cao Shuang, Tian Xue et al. Lower Serum Potassium Levels at Admission are Associated with the Risk of Recurrent Stroke in Patients with Acute Ischemic Stroke or Transient Ischemic Attack.[J]. *Cerebrovasc Dis*, 2022, 51: 304-312.
- 13) Mattern Lindsey, Chen Cheng, McClure Leslie A et al. Serum Zinc Levels and Incidence of Ischemic Stroke: The Reasons for Geographic and Racial Differences in Stroke Study.[J]. *Stroke*, 2021, 52: 3953-3960.
- 14) Park Jun Young, Kim Ju Hyeon, Sim Young Joo et al. The association between the serum vitamin D levels and the stroke lesion size, functional ability, and cognition in elderly Korean ischemic stroke patients.[J]. *Medicine (Baltimore)*, 2022, 101: e04086.
- 15) Zhang Xiaopeng. Correlation between serum HMGB1 and sTLT-1 levels and oxidative stress response and endothelial injury in patients with ischemic stroke[J]. *Journal of Hainan Medical College*, 2017, 23 (21): 3021-3024.
- 16) Yang Pinni, Zhu Zhengbao, Shi Mengyao et al. Association of serum growth differentiation factor-15 levels with the risks of death and vascular events in patients with ischemic stroke: The role of diabetes.[J]. *Nutr Metab Cardiovasc Dis*, 2022, 32: 616-623.
- 17) Chauhan Himanshu, Atam Virendra, Sawlani K K et al. Role of Serum Homocysteine, C-Reactive Protein (CRP), Uric Acid & Pro-Brain Natriuretic Peptide (Pro-BNP) in Predicting the Functional Outcome in Patients with Ischemic Stroke- A Prospective Observational Study from North India.[J]. *J Assoc Physicians India*, 2022, 70: 11-12.
- 18) Zhang Kaixin, Zhu Zhengbao, Shi Mengyao et al. Serum Dickkopf-1 levels and poststroke depression in ischemic stroke patients.[J]. *J Affect Disord*, 2022, 310: 337-342.
- 19) Yang K, Fan M, Wang X, Xu J, Wang Y, Tu F, Gill PS, Ha T, Liu L, Williams DL, Li C. Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis. *Cell Death Differ*. 2022 Jan; 29(1): 133-146.
- 20) Liu Jing, Shi Min, Ji Musen, Jin Zhaochen. Correlation analysis of serum NSE, S100- $\beta$  and HMGB1 with the severity and prognosis of ischemic stroke [ J ]. *Chinese Journal of Emergency Resuscitation and Disaster Medicine*, 2021, 16 (11): 1256-1258+1269.
- 21) Zhang Jun-Fang, Meng Xia, Jing Jing et al. Serum calcium and long-term outcome after ischemic stroke: Results from the China National stroke registry III.[J]. *Atherosclerosis*, 2021, 325: 24-29.
- 22) Meng Lin-Lie, Cao Li, Serum neopterin levels and their role in the prognosis of patients with ischemic stroke: A systematic review and meta-analysis.[J]. *J Clin Neurosci*, 2021, 92: 55-60.

- 23) Zang Yuhan, Zhu Zhengbao, Xie Yi et al. Serum Growth Differentiation Factor 15 Levels Are Associated With Depression After Ischemic Stroke. [J]. J Am Heart Assoc, 2022, 11: e022607.
- 24) Zhang Tian, Chen Xuexu, Xing Mengyun, Wang Tan. The effect of serum OxA and A $\beta$  (1-42) on cognitive impairment after ischemic stroke and the predictive value of diagnosis [J]. Chinese Journal of Geriatrics, 2019, 39 (24): 5937-5940.
- 25) Qin Xue, Zhao Weijin, Dong Chunyao. Analysis of serum PAI-1 and A $\beta$  levels in patients with acute ischemic stroke and their correlation with the severity of the disease [J]. Journal of Clinical Emergency, 2017, 18 (04): 270-272+276.

---

*Corresponding Author:*

YANAN ZHANG

Email: guzhong2886174947@163.com

(China)